The booming pharmaceutical market of China presents humongous opportunities for pharmaceutical companies all over the world. The fast growing Chinese market which is poised to be the world's third largest pharmaceutical market by 2012 , is expected to grow to $100 billion by 2015. It is all set to become the world’s number one pharmaceutical market by 2020, according to some estimates.
According to IMS Health , China is already the world's third-largest pharmaceutical market. Growth is expected to climb to between 25 to 27 per cent this year compared with a global growth rate of five to seven per cent last year.
Increasing healthcare demands within its own borders as well as fuelled by international companies looking for manufacturing facilities, China's hunger for foreign partnerships and high-quality pharmaceutical ingredients presents great opportunities to international suppliers.
CPhI China, leading exhibition for the medical and pharmaceutical industry, being organized by UBM Asia Ltd ,which will be held from June 21 to 23 , 2011 at Shanghai New International Expo Centre (SNIEC) in China, gains special significance in this context. CPhI China is a sister brand of CPhI Worldwide - the "must attend" event in the international pharmaceutical industry.
The latest edition is expected to be the largest edition of CPhI China and has co-located events – P-MEC China, which covers pharma machinery and equipment, ICSE China, which looks at outsourcing solutions, BioPh China, which showcases the biopharma sector and the LABWorld pavilion for laboratory, analytical and biotechnology instrumentation technologies.
Thus CPhI China and its co-located events is a unique gateway to the China pharma universe and is the most international pharmaceutical industry events in China.
After a successful 2010 event, CPhI China is expected to grow further in 2011. The events are projected to host over 27,000 attendees with 2,000 exhibitors, including many key players in all aspects of China’s expanding pharma industry. Being the most significant international pharma event in China, this fair serves to act as a conduit for attendees to gain accurate market knowledge and competitor intelligence.
“China’s pharma market is expected to become the third largest in the world in 2011. The strength of China’s industry allows the brands to consistently deliver a quality event in a growing market that is also forward thinking,” Annemieke Timmers, Brand Director for CPhI noted. “China is at the centre of health reforms. The government has recently provided US$ 125 billion in incremental funding to increase medical insurance coverage to all city residents and 90 per cent of the rural population.”
CPhI China and co-located events will have a few new introductions in 2011. Most notable, is the addition of the first modular conference programme for the events, with relevant topics in the current market, such as API sourcing strategy, compliance, reduction of cost and maximizing competitive strategies in generics. Also new is the addition of LABWorld pavilion to the P-MEC event which will cater to small scale laboratory and analysis needs. This new pavilion will couple with P-MEC to host over 320 suppliers.
“It is clear that China’s pharma market growth looks very positive for the future based on past figures and current projections. Within the past five years, markets in second and third-tier cities within China have grown 28 per cent and 47.5 per cent respectively,” commented Haf Cennydd, Event Director of ICSE/P-MEC/BioPh/LABWorld China.
“We have structured the events to offer specific solutions for the current market demands. For example, introductions such as LABWorld, located in the P-MEC event have been tailored to the lab and analytics sectors of the pharmaceutical market”, she added.
The inaugural China conference series, titled “Pharma R&D and Collaboration Strategies”, will address global pharmaceutical issues, with an emphasis on China’s pharma market, across key areas such as new drug discovery, biopharm, biosimilars, CRO/CMO, API sourcing, generics and export strategies and more. It will bring together Chinese and global pharma companies to explore different views regarding the China pharmaceutical market.
About 30 eminent speakers from international pharmaceutical companies and research institutes, such as the FDA, Novartis, USP-China, Roche R&D Center, GSK China/HK, AstraZeneca Innovation Centre China, Sanofi-Aventis, REVA PHARMA, Dr. Reddy's and Shanghai Pharma, will share their knowledge and research strategies. Additionally, in-depth case studies covering R&D and business development strategies will be presented by an outstanding panel of Chinese, Indian and international speakers from industry leading companies and associations.
The introduction of the conference programme to the China events follows the successful launch of a similar series at the CPhI Worldwide, CPhI South America and CPhI India events and is expected to draw over 400 attendees.
CPhI China mirrors the growth of Chinese industries over the last decade and it showcases its excellence in the medical and pharma industry. With China’s initiative in the R&D and innovation, this fair opens up the doors for international exhibitors to impress an eager Chinese market.
The participants in the event will be able to
- Meet with key decision makers in pharmaceutical industry from 102 countries, including China, India, US, UK, France, Italy etc
- Discover potential partners who can make the connection between products and local productivity
- Find all major Chinese suppliers of pharmaceutical ingredients, outsourcing, equipment and bio-solutions in one location
- Source ingredients and services at competitive prices
- Learn about the latest innovations, technologies, trends and developments in China's pharmaceutical industry at the CPhI China Conferences
Network and gain access to one of the world's fastest growing pharmaceutical markets
Thus the event provides a viable platform of launching new products/services and proves to be effective in enhancing knowledge about the respective sector. It will help an exhibitor to present brand and products to more than 20,000 key decision makers in China's pharmaceutical industry. It will help to enhance brand awareness, develop business relationships, launch new products and increase market knowledge.
The exhibitor profile includes active pharmaceutical ingredients, alkaloids, amino acids, antibiotics, antibodies, antimicrobial preservatives, antioxidants, biocatalysts, biotechnology, capsules/encapsulation, chemical synthesis/analysis, chira intermediates, coating agents, colour and dispersions, custom manufacturing, cytokines, emulsifying/solubilising agents, enzymes, excipients, drug formulation, fine chemicals, flavours and perfumes, glidants, herbal teas, hormones & synthetic substances, immunochemistry, intermediates, medicinal plants, microencapsulation, ointments bases, peptides, phospholipids, plant/animal extracts, prostaglandins, publishers, purification and separation techniques, regulatory affairs, sera and vaccines, solvents, stiffening agents, stiffening bases, suppository bases, suspending/viscosity, increasing agents, sweetening agents, synthetic organic chemistry, tablet binders, tablet disintegrants, tablet filler-binders, tablet lubricants, tissue culture medias and wetting/solubilising agents
CPhI China is attracting more and more visitors every year. They include specialists from general management, marketing & sales, purchasing, production, quality control, engineering and R&D. On average, over 70 per cent of all visitors have purchasing power. Decision-makers from all sectors of the pharmaceutical industry will be searching for new products, services and deals.
CPhI China has been organized in China since its launch in 2001.Sprawled on an area of more than 82,000 square meters, CPHI China 2010 had achieved a huge success in providing the perfect business environment to pharmaceutical industry.About 54 world class conferences and seminars not only illuminated the pharma industry but also offered exhibitors and visitors enormous opportunities to exchange the latest medical information. It was hosted along with ICSE & BioPh China 2010 and P-MEC China 2010.
The global VIP trade delegation had offered the opportunity for visitors to go at the site of some of the leading companies situated in mainland China. Poised as a leading pharma event, CPHI China 2010 offered wide business potential to medical professionals for forming alliances and to do business with more than 25,000 of their industry peers. Altogether over 2000 companies attended the show including overseas companies from Germany, Italy, France, Switzerland, India, UK, USA and many more.With such a large visitor base, this trade fair has been widely acclaimed as one of the best in the pharmaceutical industry.